What's in Mundipharma Korea Ltd's pipeline?

Mundipharma Korea Ltd has 5 drugs in our index: 5 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Mundipharma Korea Ltd's portfolio?

Top competitors by shared drug class: GlaxoSmithKline, Ain Shams University, Asbjørn Mohr Drewes, Allergy and Asthma Center of El Paso, Alza Corporation, DE, USA.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/mundipharma-korea-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Mundipharma Korea Ltd — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mundipharma Korea Ltd pipeline: 5 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Oxycodone(single compound)	Oxycodone(single compound)	marketed	Opioid analgesic	Mu (μ) opioid receptor	Pain Management
Brand Name: Targin®	Brand Name: Targin®	marketed
Fluticasone/Formoterol	Fluticasone/Formoterol	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA)	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (formoterol)	Respiratory/Pulmonology
Lodotra®	Lodotra®	marketed	Corticosteroid (modified-release formulation)	Glucocorticoid receptor	Immunology / Rheumatology
Targin	Targin	marketed			Other

Therapeutic area mix

Immunology / Rheumatology · 1
Other · 1
Pain Management · 1
Respiratory/Pulmonology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 2 shared drug classes
Ain Shams University · 1 shared drug class
Asbjørn Mohr Drewes · 1 shared drug class
Allergy and Asthma Center of El Paso · 1 shared drug class
Alza Corporation, DE, USA · 1 shared drug class
Archimedes Development Ltd · 1 shared drug class
Ajay Wasan, MD, Msc · 1 shared drug class
AdventHealth · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Mundipharma Korea Ltd:

Cite this brief

Drug Landscape (2026). Mundipharma Korea Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mundipharma-korea-ltd. Accessed 2026-05-17.